Designing efficient, individualised cancer medicines requires an understanding of how cancer develops. For many years, scientists have understood that certain kinds of gene mutations are the origin of cancer.
Chemotherapy treatments produce strong side effects. A new agent that accumulates in the tumour tissue and is activated there by ultrasound waves does not have this problem.
According to new research, a biomarker signature can predict how well kidney cancer patients will respond to immunotherapy before treatment even starts. This biomarker signature is made up of the number of immune cells in and around kidney tumours, the volume of dead cancer tissue, and mutat
Isolated from other cells in a laboratory dish, tumour cells won't reveal their actual nature. Rice University researchers created an improved tumour model that houses osteosarcoma cells alongside immune cells known as macrophages inside a three-dimensional framework designed to simulate bon
Personalization of cancer treatments has long been a goal--finding the right drugs that work for a patient's specific tumour based on specific genetic and molecular patterns. Many of these targeted therapies are highly effective, but they are not available for all cancers, including NSCLCs w
Researchers at the Perelman School of Medicine at the University of Pennsylvania have been working on a preclinical study that focuses on a novel strategy that uses a "one-two punch" to assist T cells in attacking solid tumours. The results, which were reported in the Proceedings of the Nati
A new weapon in the arsenal of cancer cells' treatment resistance, according to a study conducted by the Garvan Institute of Medical Research, is the ability for them to respond randomly to chemotherapy.
An advanced imaging method is showing promise as a way to improve the diagnosis of prostate cancer by giving clinicians a clearer view of suspected tumours during biopsy.
An advanced imaging approach is showing promise in improving prostate cancer detection by providing doctors with a clearer image of suspected tumours during the biopsy.
According to recent research led by the Garvan Institute of Medical Research, cancer cells have an inbuilt randomness in their capacity to respond to chemotherapy, which is another weapon in their treatment resistance toolbox.